Navigation Links
Diabetes Patients with High Triglycerides and Low HDL Cholesterol Get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
Date:2/26/2009

y 11%, P=0.035). This was mainly driven by 24% reduction in nonfatal MI (P=0.01) and 21% reduction in coronary revascularisation (P=0.003).(5)

There was also evidence of benefit with fenofibrate for microvascular endpoints, in particular reduction in first laser treatment for retinopathy (by 31%, P=0.0002).(6, 7)

What is the metabolic syndrome?

The metabolic syndrome is characterised by a clustering of cardiovascular risk factors which increase the risk of type 2 diabetes and cardiovascular disease. Although the definition of metabolic syndrome varies among different guidelines, one of the most widely accepted is that of the NCEP ATPIII(4) which defines metabolic syndrome by the following criteria:

    -- Abdominal obesity (waist circumference >40 inches in men and
       >35 inches in women) AND
    -- Triglycerides greater than or equal to 150 mg/dL
    -- HDL cholesterol <40 mg/dL in men and <50 mg/dL in women
    -- Blood pressure greater than or equal to 130/85 mmHg (or on
       antihypertensive treatment)
    -- Elevated fasting plasma glucose (greater than or equal to 100 mg/dL).

What is meant by number needed to treat?

The NNT value provides a clinical context to the absolute reduction in risk. This value is defined by the inverse of the absolute reduction in risk. In this analysis, the NNT for fenofibrate in patients with marked atherogenic dyslipidaemia was 23 patients needing to be treated for one event to be prevented.

By comparison, the Cholesterol Treatment Trialists' (CTT) Collaborators (8) reported an absolute reduction in 5-year risk of major vascular events in diabetes patients treated with statin therapy of 3.6%, i.e. NNT = 28.

References

1. Russell Scott, Richard O'Brien, Greg Fulcher, Chris Pardy, Michael d'Emden, Dana Tse, Maria-Riitta Taskinen, Christian Ehnholm, Anthony Keech
'/>"/>

SOURCE Solvay
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. February 2009 Mayo Clinic Womens HealthSource Highlights Diabetes and Heart Disease, Going Vegetarian and Tinnitus
2. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
3. Arena Pharmaceuticals Announces Initiation of Phase 1 Clinical Trial of Type 2 Diabetes Drug Candidate in Partnership with Ortho-McNeil-Janssen Pharmaceuticals
4. Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
5. Overweight Siblings of Children With Type 2 Diabetes Likely to Have Abnormal Blood Sugar Levels
6. Patient Recruitment Begins in India for Phase 3 Diabetes Trial
7. Opportunities to Highlight Type 1 Diabetes in November
8. Oramed Pharmaceuticals Chosen to Present Results of GLP-1 Analog Enteral Administration Study at the Diabetes Technology Societys Eighth Annual Meeting (November 13-15, 2008; Bethesda, Maryland)
9. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
10. TAXUS(R) Express(R) Stent Shows Similarly Low Re-Intervention Rates in Patients With Diabetes Compared to Non-Diabetics in Arrive Registry Program
11. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015 BioElectronics Corporation ... ActiPatch® Musculoskeletal Pain Therapy medical devices, announced today ... its ActiPatch 7-day trial device has been published ... Pain Management http://www.futuremedicine.com/doi/full/10.2217/PMT.15.35 .  More than ... and submitted an assessment.  Chronic ...
(Date:8/4/2015)... KNOXVILLE, Tenn., Aug. 4, 2015 Second ... million; 30.1% over second quarter of 2014 , Net ... $28.9 million; $51.2 million after adjustments , Diluted net ... , Adjusted EBITDA increased 15.2% to $99.4 million ... increased to a range of 24.0% to 26.0%; Adjusted EBITDA ...
(Date:8/4/2015)... Minn., Aug. 4, 2015 ANI Pharmaceuticals, Inc. ... for the three and six months ended June 30, ... Company will host its earnings conference call this morning, ... other interested parties can join the call by dialing ... Year-to-Date Highlights Include: , Year-to-date net revenues of ...
Breaking Medicine Technology:BioElectronics' Landmark 5,000+ Chronic Pain Patient Study Published in Pain Management Medical Journal 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 2Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 3Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 4Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 5Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 6Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 7Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 8Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 9Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 10Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 11Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 12Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 13Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 14Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 15Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 16Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 17Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 18Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 19Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 20Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 21Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 22Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 23Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 24Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 25Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 26Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 27Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 28Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 29Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 30Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 31Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 32Team Health Holdings, Inc. Announces Second Quarter 2015 Financial Results 33ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 2ANI Pharmaceuticals Reports Second Quarter and Year-To-Date 2015 Results and Highlights 3
... International Holdings, Inc. (NYSE Amex: BONE ... bone graft material and antimicrobial coatings for medical ... three-year agreement with Novation, a leading health care ... provides Bacterin,s full biologic portfolio, including OsteoSponge®, OsteoSelect® ...
... Fla., May 8, 2012 Grappling with economic uncertainty, ... industry is on the cusp of major changes, said ... opening session of the 2012 GHX Healthcare Supply Chain ... GPOs and distributors gathered this week in Orlando for ...
Cached Medicine Technology:Bacterin International Signs Its Third National GPO Contract with Novation 2Bacterin International Signs Its Third National GPO Contract with Novation 3Bacterin International Signs Its Third National GPO Contract with Novation 4GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 2GHX Reveals Roadmap to Stronger Healthcare Community at GHX Healthcare Supply Chain Summit 3
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... Many men ... on the subject, Renew Man™ is standing up as a voice of authority for ... of the healthy aging industry with special experience and expertise in the safe and ...
(Date:8/4/2015)... ... ... 24/7 Care At Home , a provider of comprehensive home health ... the U.S. Department of Veteran’s Affairs (VA) has awarded its agency a rating of ... the path to meeting the aspirational goals the VA promotes each year. , ...
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... , ... August 04, 2015 , ... ... firms and government entities, today announced that John Munro, a 15-year veteran of ... President of Managed Services Operations. , “I am thrilled to join Discovia at ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... announced that Bruce McCalley joins its executive leadership team as Senior Vice President ... success at technology companies and expanding global markets with a special emphasis on ...
Breaking Medicine News(10 mins):Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 2Health News:New Video from Renew Man™ Raises Awareness of the Right Way to Correct Low Testosterone 3Health News:24/7 Care At Home Receives Two Stars from the VA 2Health News:24/7 Care At Home Receives Two Stars from the VA 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 2Health News:John Munro Joins eDiscovery Leader Discovia as Vice President of Managed Services Operations 3Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 2Health News:SanusEO Hires Healthcare Technology Executive Bruce McCalley As Senior Vice President of Sales & Marketing 3
... conducted by the anthropologists, from the University of Connecticut, University ... , ,They said that Neanderthals were very good in hunting ... modern humans. ,But the early modern humans ... due to the competition they received from the early modern ...
... by scientists belonging to the Northwestern University targeted at ... //The gene therapy, described in the January online issue ... Bohn and her laboratory group at Northwestern University Feinberg ... Medical Research Council Professor and director of the neurobiology ...
... on the rise and is rapidly becoming the number one cancer ... seriousness of the situation is apparent after going through recent data ... ,The rise is being documented mainly in the metros, but it ... unnoticed. It is reported that one in 22 women in India ...
... more than a couple of seconds to decide whether the ... findings. The decision is often taken in less than a ... impossible to really see anything in less than 500 milliseconds,’ ... has published the research in the journal Behavior and Information ...
... improvements made in diagnoses and treatment of the fatal ... a cure rate of 90%, according to researchers belonging ... ,The progressive improvement in the cure rate since ... reflects in large part the more effective use of ...
... to medical science, doctors under the leadership of Dr Hasan ... would perform surgery on patients while they// are in a ... out from their bodies while the surgery is being performed ... is complete. ,The return of blood would be ...
Cached Medicine News:Health News:Acute Lymphoblastic Leukemia May Attain a 90% Cure Rate 2
... Sensor is the first sensor designed specifically ... sensor is the first and only sensor ... and children. Cyanotic infants and children ... and accurate pulse oximetry, and Masimo's research ...
ELISA kit for Varicella-zoster IgG detection....
... Virus (VZV) IgG Enzyme-Linked Immunosorbent Assay (ELISA) ... determination of IgG antibody to VZV in ... be used for the determination of immune ... be used to demonstrate seroconversion or a ...
Inquire...
Medicine Products: